Introduction
Amiodarone has been used widely in Europe as an antianginal and antiarrhythmic drug for more than 15 years (Vastesaeger, Gillot and Rasson, 1967) . Though available on a named-patient basis in Britain from 1973 (Chamberlain and Clark, 1977) , it was licensed for limited clinical use only in early 1981. Acute toxicity does not occur readily with oral amiodarone and the drug is considered relatively safe. Unwanted effects during maintenance therapy include photosensitivity (Rosenbaum et al., 1976) , minor ocular effects (Franqois, 1969) , and disorders of thyroid function (Massin et al., 1971 ).
We have noticed frequent discordance between the results of thyroid function tests and clinical status in our patients treated with amiodarone: we report our experience of the relationship gained over 8 years of observations and advance hypotheses which may account for apparently anomalous results.
Patients and methods
Serial thyroid function tests were performed on 100 patients treated with amiodarone for 6 weeks to 8 years. Their ages ranged from 33 to 92 years (mean 66 years). All were judged clinically euthyroid when amiodarone was started.
Amiodarone was administered in doses of 600 mg daily for 1 week, 400 mg daily for 1 week, and 200 mg daily subsequently. Once we appreciated how frequently the drug could affect thyroid hormone metabolism we measured thyroid function tests before treatment started and at least 6-monthly thereafter. A total of 53 patients had both baseline and follow-up tests. Most of our earlier patients who had been on treatment for up to 8 years were recalled for the purposes of this study, and 41 of them had only a single test at that time. The remaining 6 patients had serial tests which started after therapy had been commenced.
The free thyroxine index (FTI) was used as the routine screening test in all 100 patients, being derived from the total serum thyroxine (Ratcliffe et al., 1974) (Grundy, 1979) , the total serum tri-iodothyronine using the Amerlex T3 radioimmunoassay kit (Amersham International), the serum thyroid binding globulin (TBG) (Grundy, 1979) , and the thyrotrophin releasing hormone (TRH) test using 200,ug TRH with measurements of thyrotrophin (TSH) by radioimmunoassay (RIANEN TSH radioimmunoassay Kit, New England Nuclear).
In 5 healthy volunteers all these thyroid function tests together with measurement of serum reverse triiodothyronine (rT3) by radioimmunoassay (Mathur et al., 1979) were performed before and after 2 weeks treatment with 600 mg amiodarone daily.
In another 9 healthy subjects thyroid function was investigated similarly before and after treatment with 18 mg iodine daily, as diluted Lugol's iodine. This amount of iodine is equivalent to that released from 600 mg amiodarone (Broekhuysen, Laruel and Sion, 1969 (102 ±20) (P<0.001).
Healthy subjects
The results from 5 healthy subjects given 600 mg amiodarone daily for 2 weeks are shown in Table 1 . In this group there was no significant change in FTI, free thyroxine, or tri-iodothyronine, but there was a significant rise in rT3 from a mean of 0.59 to 1.47 nmol/litre (P<0.001).
Nine normal subjects treated for 2 weeks with iodine equivalent to that released from 600 mg amiodarone showed no significant change in FTI, free thyroxine, tri-iodothyronine, or rT3, indicating that the rise in rT3 on amiodarone was not due simply to its iodine content.
Discussion
Amiodarone which contains 75 mg iodine per 200 mg of active substance, bears a structural similarity to thyroxine (Fig. 1) . It might affect thyroid function for two reasons: firstly because of its iodine content, and (Massin et al., 1971) . The iodine released from usual therapeutic doses of amiodarone would not, however, be likely to reduce appreciably thyroid hormone release in normal glands, though it could certainly do so in patients with Graves' disease (Wolff, 1969) . The observations in our healthy subjects treated with iodine equivalent to that released from amiodarone confirmed this: no significant effect was demonstrable on thyroid function. Similarly, though iodine may provoke hyperthyroidism where there is pre-existing iodine deficiency it very rarely does so in normal glands (Savoie et al., 1975) .
Amiodarone can also influence thyroid hormone metabolism by inhibiting the peripheral conversion of thyroxine to tri-iodothyronine, and enhancing its alternative pathway to reverse tri-iodothyronine, which is metabolically inactive .
Ten of our 100 patients on long-term amiodarone developed latent or overt hypothyroidism, and one developed hyperthyroidism. Our experience suggests that the development of hypothyroidism during amiodarone therapy is more likely to occur if there is some predisposition to it: the mean pre-amiodarone FTI, while within the normal range, was significantly lower in our patients who developed hypothyroidism than in the series as a whole.
The diagnosis of hyperthyroidism may present considerable difficulty in patients on amiodarone for two reasons. Firstly, the major clinical manifestation of the disease in the elderly may be cardiac, which will be modified by amiodarone; secondly, circulating thyroxine may be raised without clinical manifestations of thyrotoxicosis. Weight loss and heat intolerance were helpful features in our single thyrotoxic patient, whose FTI was also the highest recorded in our patients. The simultaneously normal tri-iodothyronine in this patient was unexpected, but her flat TSH response suggests that her intrapituitary tri-iodothyronine level was high. Perhaps intracellular tri-iodothyronine elsewhere was also high, producing her clinical hyperthyroidism. That the thyrotoxicosis in this patient was induced by amiodarone is inferred from its disappearance on withdrawal of the drug without the need for other therapy.
The striking feature in 25% of our patients was the raised FTI, though they remained euthyroid due to their normal tri-iodothyronine levels. This can be explained by amiodarone-induced inhibition of the conversion of thyroxine to tri-iodothyronine, with diversion of thyroxine to rT3. This was first postulated by Burger et al. in 1976, and has been described with other drugs including dexamethasone (Chopra et al., 1975) , propranolol (Verhoeven et al., 1977) , and radiographic contrast media such as iopanoic acid (Biirgi et al., 1976 ). This does not, however, explain the raised thyroxine levels in our patients on amiodarone, and in the 12 patients described by Pritchard et al. (1975) . Raised thyroxine levels could be due to inhibition of hepatic uptake of thyroxine as has been observed with radiographic contrast agents (Felicetta, Green and Nelp, 1980) . Alternatively, raised thyroxine levels may be due to enzyme inhibition by amiodarone, since the same enzyme is required both for in vitro conversion of thyroxine to tri-iodothyronine and for the completion of the alternative pathway from rT3 to one of its metabolites, di-iodothyronine (Kaplan and Utiger, 1978) .
The TRH tests were usually normal in our patients in spite of raised thyroxine levels, consistent with their normal tri-iodothyronine concentrations. But both exaggerated and flat responses to TRH were seen in clinically euthyroid patients with normal triiodothyronine and raised thyroxine levels. These anomalous responses suggest that intrapituitary levels of tri-iodothyronine are not necessarily reflected by circulating levels. The pituitary derives relatively more tri-iodothyronine from thyroxine than do other tissues (Silva and Larsen, 1978 
